Entrada Therapeutics, Inc. (TRDA) Stock Analysis & Investment Frameworks
Entrada Therapeutics, Inc. (TRDA) stock analysis on Invetso. Review Entrada Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Entrada Therapeutics, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Entrada Therapeutics, Inc. Key Financial Metrics
- Market Cap: $181.06M
- Revenue: $25.42M
- ROE: -57.61%
- ROIC: -62.61%
- Dividend Yield: N/A
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Entrada Therapeutics, Inc. Investment Frameworks
Invetso analyzes Entrada Therapeutics, Inc. (TRDA) across the following frameworks:
- Entrada Therapeutics, Inc. 10Y Growth Potential
- Entrada Therapeutics, Inc. Scenario Analysis
- Entrada Therapeutics, Inc. Risks & Opportunities
- Entrada Therapeutics, Inc. Economic Moat
- Entrada Therapeutics, Inc. Business Model
- Entrada Therapeutics, Inc. Management
- Entrada Therapeutics, Inc. SWOT Analysis
- Entrada Therapeutics, Inc. Porter's 5 Forces
- Entrada Therapeutics, Inc. PESTLE Analysis
- Entrada Therapeutics, Inc. ESG Analysis